 - Company licenses exclusive worldwide rights to develop, manufacture and commercialize targeted, highly specific immunosuppressive therapeutic proteins for the potential treatment of neuromyelitis optica spectrum disorder NMOSD from Julius-Maximilians-University of Wuerzburg, Germany - Initial step in growth strategy to build-out pipeline of assets - Aeterna Zentaris to develop potential therapeutic treatment option for neuromyelitis optica spectrum disorder NMOSD, an orphan indication with strong unmet medical need and significant market opportunity 